The present invention relates to a process for the preparation of fungicidally active triazole compounds wherein said process uses homologous cage amines as the catalyst.

The present invention relates to a process for the preparation of fungicidally active triazole compounds wherein said process uses homologous cage amines as the catalyst.

Disclosed herein is a process for preparation of 1-chloro-2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)propan-2-ol (compound of formula (I)) 5 and 2-(1-chlorocyclopropyl)-2-[(2-chlorophenyl)methyl]oxirane (compound of formula (II)).

Disclosed herein is a process for preparation of 1-chloro-2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)propan-2-ol (compound of formula (I)) 5 and 2-(1-chlorocyclopropyl)-2-[(2-chlorophenyl)methyl]oxirane (compound of formula (II)).

A method is described for preparing cyclopropyl-substituted acetophenones of the general formula (I). ##STR00001##

A method is described for preparing cyclopropyl-substituted acetophenones of the general formula (I). ##STR00001##

A method is described for preparing cyclopropyl-substituted acetophenones of the general formula (I).

##STR00001##

A method is described for preparing cyclopropyl-substituted acetophenones of the general formula (I).

##STR00001##

Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.